NCT02744209View on ClinicalTrials.gov

Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients

TerminatedOBSERVATIONAL
Enrollment

17

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions
Stage IV Melanoma
Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Mayo Clinic

OTHER